Lynkuet ingår nu i läkemedelsförmånen!
Subventioneras endast för behandling av måttliga till svåra vasomotoriska symtom orsakade av adjuvant endokrin behandling relaterad till bröstcancer.

Xofigo mediabibliotek

Introduction to Radium-223 in clinical practice teaser

Episode No. 1 - Introduction to Radium-223 in clinical pr...

Learn about the development and unique properties of Radium-223.

Introduction to clinical evidence for Radium-223 Teaser

Episode No. 2 - Introduction to clinical evidence for Rad...

Explore findings from the pivotal ALSYMPCA trial and its impact on treatment.

Introduction to monitoring and management during Radium-223 treatment Teaser

Episode No. 4 - Introduction to monitoring and management...

Discover essential monitoring practices for effective patient management.

Introduction to post-radium-223 treatment options teaser

Episode No. 5 - Introduction to post-radium-223 treatment...

Discuss next steps for patients after completing Radium-223 therapy.

Video series on advanced prostate cancer management teaser

Welcome video for the series Episode 1-5

Join Dr. Daniel Heinrich, a clinical oncologist from Norway, and Dr. Joe O'Sullivan from Belfast, Northern Ireland, as they share their i...

Introduction to patient selection for Radium-223 Teaser

Episode No. 3 - Introduction to patient selection for Rad...

Understand criteria for selecting ideal candidates and the role of patient education.

Xofigos verkningsmekanism

11-05-23 Bayer AS Xofigo är ett terapeutiskt alfastrålande läkemedel.

Xofigo Manufacturing in Oslo

01-07-24 Bayer AS Bayer har etablerat en unik och dedikerad produktionsanläggning för XOFIGO i Oslo - en säker och pålitlig helhetsleveranske...